1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Ranitidine Bismuth Citrate

Last updated on October 6, 2021

Drug Nomenclature

Ranitidine Bismuth Citrate
Synonyms: A complex of ranitidine and bismuth citrate; GR-122311X; Ranitidina y bismuto, citrato de; Ranitidine Bismutrex
BAN: Ranitidine Bismuth Citrate
USAN: Ranitidine Bismuth Citrate
Chemical name: N-[2-({5-[(Dimethylamino)methyl]furfuryl}thio)-ethyl]-N´-methyl-2-nitro-1,1-ethenediamine, compound with bismuth(3+) citrate (1:1)
Molecular formula: C13H22N4O3S,C6H5BiO7 =712.5
CAS: 128345-62-0
ATC code: A02BA07
Read code: y08Oh

Adverse Effects and Precautions

Ranitidine bismuth citrate would be expected to combine the adverse effects of both bismuth compounds and ranitidine. Blackening of the tongue and faeces is common, and gastrointestinal disturbances, headache, mild anaemia, and altered liver enzyme values have been reported. Rarely, hypersensitivity reactions (including anaphylaxis), have occurred. Ranitidine bismuth citrate should not be given to patients with moderate to severe renal impairment. It is not suitable for long-term or maintenance therapy because of the risk of bismuth accumulation. As with other antisecretory drugs, the possibility of malignancy should be considered when giving ranitidine bismuth citrate to patients with gastric ulcers since the drug may mask symptoms and delay diagnosis.


Ranitidine bismuth citrate would be expected to have the interactions of bismuth compounds, and ranitidine.


After oral doses, ranitidine bismuth citrate dissociates into its ranitidine and bismuth components in the stomach. For the pharmacokinetics of ranitidine, and for those of bismuth.

Uses and Administration

Ranitidine bismuth citrate is a complex of ranitidine with bismuth and citrate, which releases ranitidine and bismuth in the gastrointestinal tract and therefore possesses both the actions of the bismuth compounds and of ranitidine. It has been used in the management of peptic ulcer disease, and may be given with antibacterials for the eradication of Helicobacter pylori infection and the prevention of relapse of peptic ulcer disease.

Doses are 400 mg twice daily orally treatment has usually been given for 4 to 8 weeks for duodenal ulceration and for 8 weeks for benign gastric ulceration. Ranitidine bismuth citrate should not be used for maintenance therapy, and a maximum of 16 weeks of treatment (two 8-week courses or four 4-week courses) may be given in a 12-month period. For duodenal ulceration where H. pylori infection is present, ranitidine bismuth citrate has been given as part of a 7-day triple therapy regimen, typically combined with any two of clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, or metronidazole 400 mg twice daily. Alternatively, a 14-day dual therapy regimen of ranitidine bismuth citrate combined with clarithromycin 500 mg two or three times daily has been used. In both regimens ranitidine bismuth citrate alone may be continued to a total of 28 days.


Proprietary Preparations


Argentina: Fylorid

Austria: Helirad Pylorisin

Belgium: Fylorid

Brazil: Pylorid

Czech Republic: Eradipak

Denmark: Pylorid

Finland: Pylorid

Greece: Pylorid

Hong Kong: Pylorid

Hungary: Pyloridf

Ireland: Fylorid

Italy: Elicodil Pylorid

Mexico: Azanplus

The Netherlands: Pylorid

Norway: Pylorid

Portugal: Pylorid

Spain: Pylorid

Switzerland: Pylorid

Thailand: Pylorid

Turkey: Pylorid

UK: Pylorid

Venezuela: Pylorid.


Australia: Fylorid-KA

Leave a Reply
Notify of